Published in Cancer Res on December 15, 1988
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 3.51
Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 3.45
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 3.13
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys J (1993) 2.36
Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer (2010) 1.92
Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A (1999) 1.82
Factors determining antibody distribution in tumors. Trends Pharmacol Sci (2008) 1.80
Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem (2012) 1.55
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci U S A (2011) 1.54
In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Mol Imaging Biol (2012) 1.49
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia (1999) 1.47
The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng (2014) 1.40
Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res (2013) 1.34
Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer (2005) 1.29
Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U S A (1995) 1.27
A systems approach for tumor pharmacokinetics. PLoS One (2011) 1.27
Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer (1997) 1.25
Can engineered bacteria help control cancer? Proc Natl Acad Sci U S A (2001) 1.22
Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics (2013) 1.20
Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm (2009) 1.16
Tumor cell migration in complex microenvironments. Cell Mol Life Sci (2012) 1.16
Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. Br J Cancer (1998) 1.11
Preventing growth of brain tumors by creating a zone of resistance. Mol Ther (2008) 1.10
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer (2007) 1.08
Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurg Rev (2008) 1.06
Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS (2009) 1.06
Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev (2012) 1.04
Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One (2013) 1.03
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer (1989) 1.00
An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00
Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene (2013) 0.99
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer (1997) 0.98
Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin Cancer Res (2008) 0.97
Microfluidic platforms for mechanobiology. Lab Chip (2013) 0.97
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br J Cancer (1994) 0.96
Numerical modeling of fluid flow in solid tumors. PLoS One (2011) 0.95
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano (2014) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Multiscale models of breast cancer progression. Ann Biomed Eng (2012) 0.91
In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int J Nanomedicine (2012) 0.91
Targeted toxins in brain tumor therapy. Toxins (Basel) (2010) 0.91
Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging. Mol Imaging Biol (2013) 0.90
Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol (2014) 0.89
Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy. Br J Cancer (1992) 0.89
Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-beta. Cancer Gene Ther (2009) 0.89
Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J Control Release (2012) 0.89
Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituents. Br J Cancer (2001) 0.89
Effect of tumor shape and size on drug delivery to solid tumors. J Biol Eng (2012) 0.89
Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. Br J Cancer (1995) 0.88
Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci U S A (1995) 0.87
Numerical Modeling of Interstitial Fluid Flow Coupled with Blood Flow through a Remodeled Solid Tumor Microvascular Network. PLoS One (2013) 0.87
Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer (2000) 0.87
Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts. Br J Cancer Suppl (1996) 0.86
Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model. NMR Biomed (2011) 0.86
Numerical simulation of blood and interstitial flow through a solid tumor. J Math Biol (2009) 0.85
Elevated citrate in pediatric astrocytomas with malignant progression. Neuro Oncol (2011) 0.85
Sensitivity analysis of an image-based solid tumor computational model with heterogeneous vasculature and porosity. Ann Biomed Eng (2011) 0.85
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep (2015) 0.85
Magnetic resonance characterization of tumor microvessels in experimental breast tumors using a slow clearance blood pool contrast agent (carboxymethyldextran-A2-Gd-DOTA) with histopathological correlation. Eur Radiol (2005) 0.84
Investigations on the usefulness of CEACAMs as potential imaging targets for molecular imaging purposes. PLoS One (2011) 0.84
Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors. J Biol Eng (2014) 0.84
Non-invasive imaging of barriers to drug delivery in tumors. Microvasc Res (2008) 0.83
Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors. J Pharm Sci (2014) 0.82
Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts. AAPS J (2012) 0.82
Mathematical model of the effect of interstitial fluid pressure on angiogenic behavior in solid tumors. Comput Math Methods Med (2011) 0.82
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies. Br J Haematol (2011) 0.82
Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer (1996) 0.81
Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis. Med Phys (2010) 0.81
Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection. Mol Pharm (2006) 0.81
Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas. MAGMA (2004) 0.81
Tumour localisation kinetics of photofrin and three synthetic porphyrinoids in an amelanotic melanoma of the hamster. Br J Cancer (1993) 0.81
A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS One (2015) 0.80
Monoclonal antibody-based candidate therapeutics against HIV type 1. AIDS Res Hum Retroviruses (2011) 0.80
Preclinical evaluation of Mab CC188 for ovarian cancer imaging. Int J Cancer (2012) 0.79
Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention. Bioconjug Chem (2011) 0.79
Proton relaxation times and interstitial fluid pressure in human melanoma xenografts. Br J Cancer (1997) 0.79
Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol (2012) 0.79
Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev (2016) 0.79
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv (2010) 0.78
Evaluation of a voxelized model based on DCE-MRI for tracer transport in tumor. J Biomech Eng (2012) 0.78
Longer local retention of adoptively transferred T-LAK cells correlates with lesser adhesion molecule expression than NK-LAK cells. Clin Exp Immunol (1995) 0.78
Characterizing at-Risk Voxels by Using Perfusion Magnetic Resonance Imaging for Cervical Cancer during Radiotherapy. J Cancer Sci Ther (2012) 0.78
Mild hyperthermia influence on Herceptin(®) properties. Radiol Oncol (2015) 0.77
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2010) 0.77
Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opin Drug Deliv (2014) 0.77
Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer (2016) 0.77
PTD-mediated loading of tumor-seeking lymphocytes with prodrug-activating enzymes. AAPS J (2008) 0.77
Tumor burden talks in cancer treatment with PEGylated liposomal drugs. PLoS One (2013) 0.77
Determinants of tumor blood flow: a review. Cancer Res (1988) 5.56
Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res (1990) 3.18
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (1990) 2.61
Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation (1997) 1.71
Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: network analysis and mechanistic interpretation. Microvasc Res (1995) 1.65
Convection and diffusion measurements using fluorescence recovery after photobleaching and video image analysis: in vitro calibration and assessment. Microvasc Res (1990) 1.59
Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res (1995) 1.46
Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res (1996) 1.43
Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res (1996) 1.40
Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. Br J Cancer (1998) 1.11
Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res (1993) 1.09
Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res (1991) 1.06
Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. Cancer Res (1996) 0.99
Tumor pretargeting for radioimmunodetection and radioimmunotherapy. J Nucl Med (1998) 0.91
Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. J Nucl Med (1997) 0.79